Subscribe To
kymera therapeutics presents preclinical data demonstrating activity of kt-253, a selective heterobifunctional mdm2 degrader, in acute myeloid leukemia at the american society of hematology annual mee
A single dose of KT-253 induced rapid apoptosis and sustained tumor regression in xenograft models of AML KT-253 showed combinatorial benefit with BCL...
December 11, 2022, 3:00 pm
kymera therapeutics presents preclinical data demonstrating activity of kt-253, a selective heterobifunctional mdm2 degrader, in acute myeloid leukemia at the american society of hematology annual mee
A single dose of KT-253 induced rapid apoptosis and sustained tumor regression in xenograft models of AML KT-253 showed combinatorial benefit with BCL...
December 11, 2022, 3:00 pm
kymera therapeutics presents preclinical data demonstrating activity of kt-253, a selective heterobifunctional mdm2 degrader, in acute myeloid leukemia at the american society of hematology annual mee
A single dose of KT-253 induced rapid apoptosis and sustained tumor regression in xenograft models of AML KT-253 showed combinatorial benefit with BCL...
December 11, 2022, 3:00 pm
kymera therapeutics presents preclinical data demonstrating activity of kt-253, a selective heterobifunctional mdm2 degrader, in acute myeloid leukemia at the american society of hematology annual mee
A single dose of KT-253 induced rapid apoptosis and sustained tumor regression in xenograft models of AML KT-253 showed combinatorial benefit with BCL...
December 11, 2022, 3:00 pm
kymera therapeutics provides webcast information for december 14 investor event
Company to Share Clinical Data from KT-474 Phase I Patient Cohort and Oncology Pipeline Company to Share Clinical Data from KT-474 Phase I Patient Coh...
December 1, 2022, 7:00 am
kymera: upcoming trial data will make or break the company
kymera has some critical trial data coming up this quarter. Other IRAK4 inhibitors have been having tro...
November 8, 2022, 11:46 am
kymera therapeutics, inc. (kymr) q3 2022 earnings call transcript
kymera Therapeutics, Inc. (NASDAQ:KYMR ) Q3 2022 Earnings Conference Call November 3, 2022 8:30 AM ET C...
November 6, 2022, 1:27 am
kymera therapeutics, inc. (kymr) ceo nello mainolfi on q2 2022 results - earnings call transcript
kymera Therapeutics, Inc. (NASDAQ:KYMR ) Q2 2022 Earnings Conference Call August 9, 2022 8:30 AM ET Com...
August 10, 2022, 2:11 am
kymera therapeutics, inc. (kymr) ceo nello mainolfi on q1 2022 results - earnings call transcript
kymera Therapeutics, Inc. (NASDAQ:KYMR ) Q1 2022 Results Conference Call May 3, 2022 8:00 AM ET Company...
May 3, 2022, 6:12 pm
kymera therapeutics, inc. (kymr) reports q4 loss, lags revenue estimates
kymera Therapeutics, Inc. (KYMR) delivered earnings and revenue surprises of -83.33% and 27.78%, respec...
February 24, 2022, 11:35 am
kymera therapeutics, inc. (kymr) reports q4 loss, lags revenue estimates
kymera Therapeutics, Inc. (KYMR) delivered earnings and revenue surprises of -83.33% and 27.78%, respec...
February 24, 2022, 11:35 am
kymera therapeutics, inc. (kymr) reports q4 loss, lags revenue estimates
kymera Therapeutics, Inc. (KYMR) delivered earnings and revenue surprises of -83.33% and 27.78%, respec...
February 24, 2022, 11:35 am